Usually there are no side effects on kidneys when a reasonable dose of rosiglitazone tartrate dispersible tablets is taken under doctor’s supervision, because the drug is not metabolized through the kidneys. Rosiglitazone Tartrate Dispersible Tablets belongs to the class of thiazolidinediones, which can lower sugar by increasing the sensitivity of peripheral tissues to insulin. Since the drug is mainly metabolized through the liver and not usually through the kidneys, the drug does not usually cause kidney side effects to occur. It is contraindicated in patients who are allergic to the drug, in patients with hepatic or renal insufficiency, in pregnant or lactating women and in patients under 18 years of age, in patients with a history of or risk factors for heart failure, in patients with a history of cardiac disease, especially ischemic heart disease, in patients with osteoporosis or a history of nontraumatic fracture, and in patients with severe dyslipidemia. Clinical need to take rosiglitazone tartrate dispersible tablets people, it is recommended to consult the endocrinology department, under the guidance of the doctor for treatment.